MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
November 04, 2020 14:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
November 04, 2020 10:46 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
December 12, 2019 08:30 ET
|
Aprea Therapeutics
BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented...
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
December 09, 2019 15:05 ET
|
MacroGenics, Inc.
Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
December 09, 2019 11:00 ET
|
Aprea Therapeutics
74% ORR, 66% CR rate in 24 evaluable MDS patientsMedian duration of follow-up is 6.4 months BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical...
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
December 09, 2019 11:00 ET
|
Aprea Therapeutics
88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients52% of evaluable MDS patients...
Innate Pharma présente Lumoxiti®, médicament approuvé par la FDA, au congrès de l'ASH 2019
December 08, 2019 09:00 ET
|
INNATE PHARMA
L'analyse finale s'appuie sur les résultats de l'étude pivot de Phase III de Lumoxiti dans la leucémie à tricholeucocytes ; des réponses complètes et durables sont maintenues dans les données de suivi...
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
December 08, 2019 09:00 ET
|
INNATE PHARMA
Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate...
Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019
December 08, 2019 09:00 ET
|
INNATE PHARMA
MARSEILLE, France, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) shared new, long-term data from the pivotal...
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610
December 02, 2019 11:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...